Matthew Sykes
Stock Analyst at Goldman Sachs
(3.54)
# 848
Out of 4,944 analysts
205
Total ratings
46.48%
Success rate
5.52%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $7.31 | -31.60% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.03 | -25.56% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $12.81 | -49.26% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $32.36 | +39.06% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $6.03 | +32.67% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $27.45 | +74.86% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $14.86 | +14.40% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $169.08 | -5.37% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $6.08 | +64.47% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $88.00 | +42.05% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $12.66 | +10.58% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $205.72 | +16.66% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $12.46 | +108.67% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $152.75 | +11.29% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $55.10 | +1.63% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $116.41 | -31.28% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.21 | +23.97% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $159.81 | +18.89% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.71 | +145.48% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.69 | +57.99% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $28.77 | +28.61% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $41.74 | +55.73% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $185.91 | +34.47% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $4.76 | +404.20% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,292.89 | +0.55% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $11.56 | +3.81% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $477.41 | +34.06% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $117.32 | +23.59% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.97 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $7.31
Upside: -31.60%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.03
Upside: -25.56%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $12.81
Upside: -49.26%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $32.36
Upside: +39.06%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $6.03
Upside: +32.67%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $27.45
Upside: +74.86%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $14.86
Upside: +14.40%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $169.08
Upside: -5.37%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $6.08
Upside: +64.47%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $88.00
Upside: +42.05%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $12.66
Upside: +10.58%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $205.72
Upside: +16.66%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $12.46
Upside: +108.67%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $152.75
Upside: +11.29%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $55.10
Upside: +1.63%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $116.41
Upside: -31.28%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.21
Upside: +23.97%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $159.81
Upside: +18.89%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.71
Upside: +145.48%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.69
Upside: +57.99%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $28.77
Upside: +28.61%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $41.74
Upside: +55.73%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $185.91
Upside: +34.47%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $4.76
Upside: +404.20%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,292.89
Upside: +0.55%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $11.56
Upside: +3.81%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $477.41
Upside: +34.06%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $117.32
Upside: +23.59%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $48.97
Upside: -